https://orcid.org/0000-0002-5183-1117
Figures
Abstract
Background
Diagnosis of tuberculosis (TB) is still difficult. The purpose of our study was to evaluate the diagnostic accuracy of Mycobacterium tuberculosis cell-free DNA (cfDNA) for diagnosing of TB.
Methods
We searched relevant databases for studies that used cfDNA to diagnose TB. We evaluated the accuracy of cfDNA compared with the composite reference standard (CRS) and culture. True positive, false positive, false negative, and true negative values for cfDNA were obtained first, then the estimated pooled sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), diagnostic odds ratio (DOR), and the area under the summary receiver operating characteristic (SROC) curve (AUC) of cfDNA for diagnosing TB were calculated with 95% confidence intervals (CIs). Heterogeneity was determined using the I2 statistic. When the heterogeneity was obvious, the source of heterogeneity was further discussed.
Results
We included 14 independent studies comparing cfDNA with the CRS, and 4 studies compared with culture. The pooled sensitivity, specificity, PPV, NPV, DOR, and AUC of the SROC were 68%, 98%,99%, 62%, 83, and 0.97 as compared with the CRS, respectively. The pooled sensitivity, specificity, PPV, NPV, DOR, and AUC of the SROC were 48%, 91%, 92%, 60%, 5, and 0.88 as compared with culture, respectively. The heterogeneity between studies was significant.
Citation: Yu G, Shen Y, Ye B, Shi Y (2021) Diagnostic accuracy of Mycobacterium tuberculosis cell-free DNA for tuberculosis: A systematic review and meta-analysis. PLoS ONE 16(6): e0253658. https://doi.org/10.1371/journal.pone.0253658
Editor: Mohammad Mehdi Feizabadi, School of Medicine, Tehran University of Medical Sciences, ISLAMIC REPUBLIC OF IRAN
Received: February 22, 2021; Accepted: June 10, 2021; Published: June 23, 2021
Copyright: © 2021 Yu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: Yan Shi, A20200048, Hangzhou municipal health commission, http://wsjkw.hangzhou.gov.cn/ Guocan Yu, 20201203B179, Hangzhou Science and Technology Bureau, http://kj.hangzhou.gov.cn. The funders do not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Tuberculosis [TB] is a chronic infectious disease caused by Mycobacterium tuberculosis (MTB) that can involve any organ or system in the body [1]. Ten million new cases of TB and approximately 1.5 million TB-related deaths occurred in 2019, illustrating the global public health importance of the disease [2]. MTB most commonly infects the lungs, causing pulmonary tuberculosis (PTB); infection of organs other than the lungs is known as extrapulmonary tuberculosis (EPTB) [3, 4]. Rapid early diagnosis of PTB and EPTB is critical to control the disease and prevent its transmission, as delayed diagnosis leads to delayed treatment and enables disease spread [5]. However, rapid early diagnosis is difficult because of the low sensitivity of the acid-fast bacillus (AFB) smear, long MTB culture time, and atypical diagnostic imaging findings [6]. Although modern immunology and molecular biology techniques have improved diagnostic sensitivity and detection speed compared to classical microbiological methods, many problems remain regarding standardization of testing results and applicability of testing in various populations [7]. Breaking the TB transmission cycle requires the development of a rapid, accurate, and highly effective diagnostic test.
Cell-free DNA (cfDNA) is composed of extracellular DNA fragments released from original cells and exists in a cell-free state in various body fluids [8]. First discovered in human plasma by Mandel and Metais in 1948, cfDNA can be detected in human plasma, synovial fluid, cerebrospinal fluid (CSF), pleural fluid, urine, prostate fluid, saliva, and other body fluids [9–11]. Use of its detection has enabled great strides in prenatal diagnosis and the diagnosis and therapeutic monitoring of cancer and other diseases [12, 13]. Recent studies have also found that cfDNA is present in a variety of pathogenic bacterial, fungal, and parasitic infections, showing its value in the diagnosis and treatment of infectious diseases [11, 14]. MTB cfDNA can be detected with high diagnostic performance within a few hours in human plasma, pleural fluid, and other body fluids by polymerase chain reaction (PCR), enabling a new approach to TB diagnosis [10, 15]. However, the diagnostic efficacy of cfDNA applications in TB is remains controversial. Therefore, we performed this systematic review and meta-analysis to assess the accuracy and utility of cfDNA testing for the early diagnosis of TB.
Methods
Design and registration
This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Diagnostic Test Accuracy (PRISMA-DTA) guidelines [16] and was registered in the International Platform of Registered Systematic Review and Meta-Analysis Protocols (registration number 2020110101) [17].
Information sources
We searched the Pubmed, Cochrane Library, Embase, China National Knowledge Infrastructure, and Wanfang databases for studies that used cfDNA to diagnose TB on November 19, 2020. References cited in the identified studies were also evaluated to identify additional studies.
Search strategy
Two investigators (GCY and YQS) designed and implemented the comprehensive search strategy for studies published in the English or Chinese language. Search strategy of PubMed was listed as follows:
- #1 "Tuberculosis"[Mesh] OR “Tuberculoses Kochs Disease” OR “Koch’s Disease” OR “Koch Disease” OR “Mycobacterium tuberculosis Infection” OR “Infection, Mycobacterium tuberculosis” OR “Infections, Mycobacterium tuberculosis” OR “Mycobacterium tuberculosis Infections”
- #2 "Cell-Free Nucleic Acids"[Mesh] OR “Cell Free Nucleic Acids” OR “Nucleic Acids, Cell-Free” OR “Circulating Cell-Free Nucleic Acids” OR “Circulating Cell Free Nucleic Acids” OR “Circulating Nucleic Acids” OR “Acids, Circulating Nucleic” OR “Nucleic Acids, Circulating” OR “Cell-Free Nucleic Acid” OR “Cell Free Nucleic Acid” OR “Nucleic Acid, Cell-Free” OR “Cell-Free DNA” OR “Cell Free DNA” OR “DNA, Cell-Free” OR cfDNA OR cirDNA OR “Cell-Free Deoxyribonucleic Acid” OR “Acid, Cell-Free Deoxyribonucleic” OR “Cell Free Deoxyribonucleic Acid” OR “Deoxyribonucleic Acid, Cell-Free” OR “Circulating DNA” OR “DNA, Circulating” OR “Cell-Free RNA” OR “Cell Free RNA” OR “RNA, Cell-Free” OR cfRNA OR cirRNA OR “Cell-Free Ribonucleic Acid” OR “Acid, Cell-Free Ribonucleic” OR “Cell Free Ribonucleic Acid” OR “Ribonucleic Acid, Cell-Free” OR “Circulating RNA” OR “RNA, Circulating”
- #3 #1 AND #2
The other four databases used a similar search strategy.
Eligibility criteria
Types of studies.
Any type of study design, such as retrospective, prospective, or case-control, were eligible for inclusion provided the study assessed the efficacy of cfDNA to diagnose TB. Studies that reported only sensitivity or specificity were excluded.
Participants.
Participants of any ethnicity, sex, or age were included provided cfDNA was used to diagnose and confirm TB infection.
Outcomes.
The sensitivity and specificity of the index test were considered the primary outcome. Sensitivity is the probability that the index test will be positive in an infected patient. Specificity is the probability that the index test will be negative in a noninfected patient [18].
Comparator test.
Single-arm studies were also included if their participants, index test, and outcomes met the inclusion criteria. Comparator tests were not mandatory.
Target conditions.
Studies that diagnosed TB using cfDNA with clear reference standards and had their full text accessible were included. True positive (TP), false positive (FP), false negative (FN), and true negative (TN) values for the index test were extracted directly or calculated from the original studies. Studies reported in languages other than English or Chinese, those with <10 participants, conference abstracts without full articles, and case reports were excluded.
Literature screening and selection
The candidate studies were imported into ENDNOTE X9.2 literature management software. The same two investigators (GCY and YQS) independently evaluated the imported studies for selecting eligible articles based on inclusion criteria by reviewing their titles and abstracts and then the full text. If there was disagreement between the two investigators, they consulted with a third investigator (YS). First, we gave the controversial literature to a third researcher for independent evaluation, then the three investigators discussed and reported the reasons for inclusion or exclusion, respectively, and then the literature was included or excluded according to the inclusion and exclusion criteria after obtaining agreement.
Data extraction
We extracted the following information from each study: first author name; publication date; country; TP, FP, FN, and TN values for the index test; type of study design; patient selection method; specimen types; target gene; PCR method; specimen condition; TB types; and other parameters. Data was independently extracted by the same two investigators who screened the literature. Any disagreement was resolved by consultation with the third investigator.
Quality evaluation
Two investigators independently evaluated study quality using the revised Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) [19]. Any disagreement was handled as noted above. Publication bias was not assessed, as per the PRISMA-DTA guidelines [16]. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) guideline was used to assess the strength of the body of evidence [20].
Data synthesis and statistical analysis
When different types of TB, target genes or PCR methods were reported in the same article, we considered them as separate studies. TP, FP, FN, and TN values for the index test in each included study were obtained first, then the estimated pooled sensitivity and specificity of cfDNA for diagnosing TB were calculated with 95% confidence intervals (CIs). Calculations were performed using Stata software version 15.0 (Stata Corp., College Station, TX, USA) with the midas command package or Meta-DiSc software version 1.4 (XI Cochrane Colloquium, Barcelona, Spain). Forest plots for sensitivity and specificity were generated using Review Manager (RevMan) software version 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark). We also calculated the pooled positive predictive value (PPV), negative predictive value (NPV), diagnostic odds ratio (DOR), and the area under the summary receiver operating characteristic (SROC) curve (AUC). Heterogeneity was determined using the I2 statistic (0% indicated no observed heterogeneity; <50% indicated minor heterogeneity; >50% indicated substantial heterogeneity) [21]. Subgroup, meta-regression, and sensitivity analyses were used to explore sources of heterogeneity when significant heterogeneity was observed. Subgroup and meta-regression analyses were performed according to TB type, specimen type, target gene, PCR method, type of study design, specimen condition, and patient selection method. At least 4 eligible studies were required to perform the meta-analysis and meta-regression analyses for predefined variable parameters; these analyses were performed using Stata software version 15.0 with the midas command package [22].
Results
Identification of studies and study characteristics
Using our designed search strategy, 172 candidate articles were obtained from the databases. We identified twelve eligible articles according to the inclusion criteria by screening the title, abstract, and full text (Fig 1) [5, 9, 15, 23–31]. The kappa index of agreement between the two investigators for selection and data extraction was 0.785 (95% CI, 0.581–0.989). Two articles that reported sensitivity without specificity were excluded [32, 33]. We also excluded three articles that did not report sensitivity and specificity [34–36] and one article that reported data from another included article [37]. The reference criteria used in three articles did not meet the inclusion criteria of this study and were excluded [10, 38, 39]. One article that simultaneously reported the efficacy of different PCR methods to detect cfDNA for PTB and EPTB diagnosis was considered as four separate studies [5], and another article that simultaneously reported the efficacy of different target gene to detect cfDNA for PTB diagnosis was considered as two separate studies [15]. Another simultaneously reported the efficacy of cfDNA for PTB and EPTB diagnosis [28]. Therefore, 18 studies were included for analysis (14 studies used CRS as the reference standard and 4 studies used MTB culture as the reference standard). Included studies were analyzed separately according to different reference standards. The included studies and their characteristics were presented in Table 1. 15 studies were conducted in TB endemic areas, 13 in China, 1 in India, and 1 in South Africa. Two studies were reported in Chinese [23, 28] and the remaining ones were reported in English. All studies focused on adults. Only one study included a subset of HIV-positive patients [31]. Ten were case-control studies, seven were prospective, and one was cohort study. The specimens used in the articles were blood, urine, CSF, pleural fluid, and peritoneal fluid. The number of samples ranged from 19 to 412 and the average sample size was 124.3.
cfDNA, cell free DNA.
Study quality
The results of the methodological study quality assessment compared with CRS and culture were shown in Fig 2. When using CRS as the reference standard, six studies had nonconsecutive patient selection, one had unclear inappropriate exclusions, and four did not include treatment response in its reference criteria; these were the major sources of bias. The risk of bias from the index test and the flow and timing was judged to be relatively low. When using culture as the reference standard, three studies had nonconsecutive patient selection, one had high bias from the flow and timing; these were the major sources of bias. The risk of bias from the index test and the reference standard was judged to be relatively low. According to the GRADE guidelines, the quality of evidence of this meta-analysis was moderate.
Methodological quality graphs (risk of bias and applicability concerns), a) compared with the composite reference standard, b) compared with culture.
Diagnostic accuracy of cfDNA for TB
Fourteen studies with 1703 participants evaluated the accuracy of cfDNA for TB diagnosis compared with CRS. The sensitivity of cfDNA ranged from 27% (20%–35%) to 100% (88%–100%). The pooled sensitivity was 68% (52%–80%) and the I2 value was 94%. The specificity of cfDNA ranged from 90% (55%–100%) to 100% (94%–100%). The pooled specificity was 98% (95%–99%) and the I2 value was 72% (Fig 3). The heterogeneity of sensitivity and specificity was significant. The pooled PPV, NPV, DOR, and AUC of the SROC were 99% (99–100%), 62% (50–75%), 83 (25–278), and 0.97 (0.95–0.98), respectively.
Four studies with 535 participants evaluated the accuracy of cfDNA for TB diagnosis compared with culture. All four studies included PTB and did not include EPTB, two studies used plasma specimens and the other two studies used urine specimens. The sensitivity ranged from 30% (16%–49%) to 64% (31%–89%). The specificity ranged from 89% (84%–192%) to 100% (82%–100%) (Fig 4). The pooled sensitivity, specificity, PPV, NPV, DOR, and AUC of the SROC were 48% (35–62%), 91% (81–96%), 92% (80–100%), 60% (49–72%), 5 (3–7), and 0.88 (0.85–0.90), respectively. The heterogeneity between studies was significant.
Meta-regression and subgroup analyses
Studies that did not report target genes were excluded from the subgroup and meta-regression analysis. When compared with CRS, the results of the meta-regression analysis are presented in Table 2. TB type (PTB or EPTB), specimen type (plasma or non-plasma), PCR method (real-time PCR or digital PCR), and type of study design (prospective or case-control) had no effect on sensitivity and specificity of cfDNA testing when compared with CRS (P >0.05). Although target gene (IS6110 or non- IS6110 [IS1081, devR]) and specimen condition (fresh or frozen) had no effect on sensitivity (P >0.05), they did significantly affect specificity (P <0.05). Patient selection method (convenience or consecutive) significantly affected sensitivity (P <0.05), but had no effect on specificity (P >0.05). However, when compared with culture, the number of included studies was limited and meta-regression analysis could not be performed.
When compared with CRS, the case-control studies all used plasma specimens for testing, so the results of the subgroup analyses were the same for these two parameters. The sensitivity, specificity, PPV, NPV, DOR, and AUC of cfDNA testing using plasma specimens in case-control studies were 78% (44%–94%; I2 = 98%), 97% (93%–99%; I2 = 88%), 97% (95–100%; I2 = 61.5%), 75% (62–88%; I2 = 98.3%), 12 (8–18; I2 = 51.2%), and 0.98 (0.96–0.99), respectively. The sensitivity, specificity, PPV, NPV, DOR, and AUC of cfDNA testing using non-plasma specimens in prospective studies were 60% (51%–69%; I2 = 79%), 100% (57%–100%; I2 = 67%), 100% (100–100%; I2 = 0.0%), 45% (35–54%; I2 = 70.3%), 97 (15–615; I2 = 63.7%), and 0.82 (0.78–0.85), respectively. The heterogeneity between studies was still significant. The sensitivity, specificity, PPV, NPV, DOR, and AUC of cfDNA testing using frozen specimens were 70% (50%–84%; I2 = 96%), 97% (94%–99%; I2 = 76%), 99% (98–100%; I2 = 52.1%), 65% (51–78%; I2 = 98.4%), 16 (10–24; I2 = 54.5%), and 0.97 (0.96–0.98), respectively. The sensitivity, specificity, PPV, NPV, DOR, and AUC of cfDNA testing using IS6110 as the target gene were 74% (51%–88%; I2 = 95%), 100% (95%–100%; I2 = 90%), 100% (99–100%; I2 = 0.0%), 66% (53–79%; I2 = 98.1%), 31 (15–68; I2 = 59.2%), and 1.00 (0.99–1.00), respectively. Heterogeneity in sensitivity and specificity was still significant. Detection of cfDNA using real-time PCR exhibited pooled sensitivity, specificity, PPV, NPV, DOR, and AUC of 64% (55%–71%; I2 = 78%), 99% (96%–100%; I2 = 27%), 100% (100–100%; I2 = 0.0%), 57% (44–71%; I2 = 92.4%), 38 (17–87; I2 = 16.9%), and 0.95 (0.93–0.97), respectively. Detection of cfDNA using digital PCR exhibited pooled sensitivity, specificity, PPV, NPV, DOR, and AUC of 44% (39%–49%; I2 = 95%), 99% (91%–97%; I2 = 56%), 96% (92–100%; I2 = 78.6%), 75% (56–94%; I2 = 99.2%), 9 (5–14; I2 = 62.2%), and 1.00 (0.90–1.00), respectively. For PTB, the sensitivity of cfDNA testing ranged from 50% (31%–69%) to 100% (88%–100%) and specificity ranged from 95% (86%–99%) to 100% (88%–100%). For EPTB, the sensitivity ranged from 40% (27%–54%) to 100% (88%–100%) and the specificity ranged from 90% (55%–100%) to 100% (94%–100%) (Fig 5A). The diagnostic accuracy of cfDNA testing according to TB type (PTB and EPTB) was presented in Table 3. Table 3 and Fig 5B showed the accuracy according to EPTB type (pleurisy, meningitis, and abdominal).
a) pulmonary tuberculosis and extrapulmonary tuberculosis. b) different types of extrapulmonary tuberculosis. PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis.
When compared with culture, the sensitivity, specificity, PPV, NPV, DOR, and AUC of cfDNA testing using plasma specimens for digital PCR were 47% (35–60%; I2 = 86.7%), 97% (86–100%; I2 = 29.2%), 98% (93–100%; I2 = 0.0%), 52% (38–66%; I2 = 36.2%), 18 (3–124; I2 = 0.0%), and 0.72 (0.63–0.81), respectively. The sensitivity, specificity, PPV, NPV, DOR, and AUC of cfDNA testing using urine specimens for real-time PCR were 44% (37–52%; I2 = 44.6%), 89% (84–93%; I2 = 47.4%), 86% (61–100%; I2 = 93.8%), 68% (63–73%; I2 = 0.0%), 4 (3–6; I2 = 0.0%), and 0.67 (0.62–0.71), respectively.
Sensitivity analysis did not identify specific articles as sources of heterogeneity in sensitivity and specificity.
Discussion
This meta-analysis evaluated the effectiveness of using cfDNA testing to diagnose TB. Rapid early diagnosis is essential to improve TB prognosis and control transmission. cfDNA testing had an overall sensitivity of 68%, specificity of 98%, DOR of 83, and AUC of 0.97 for TB diagnosis (including PTB and EPTB) compared with CRS, and sensitivity of 48%, specificity of 91%, DOR of 5, and AUC of 0.88 compared with culture, demonstrating excellent diagnostic performance. There was significant heterogeneity in sensitivity and specificity. The acquisition of the diagnosis in different types of TB is distinctive considering the differences in characteristics between PTB and EPTB, and even between different types of EPTB. Therefore, we analyzed the different types of TB separately.
When compared with CRS, the sensitivity, specificity, DOR, and AUC of cfDNA testing using plasma for diagnosis of PTB were 78%, 97%, 29, and 0.99, respectively; for diagnosis of EPTB, the sensitivity, specificity, DOR, and AUC of cfDNA testing were 65%, 99%, 61, and 0.98, respectively. These results showed that cfDNA testing has good diagnostic performance for both PTB and EPTB. For PTB, the sensitivity of cfDNA testing was higher compared with EPTB, while the specificity was lower; however, the overall diagnostic efficacy was similar. Respiratory specimens, such as sputum and bronchoalveolar lavage fluid (BALF), are typically used to diagnose PTB but obtaining these specimens can be difficult, particularly in children [40]. Moreover, the diagnosis of PTB is difficult when the patient does not cough up sputum or is unable to collect sputum of acceptable quality. Although it may be possible to obtain BALF via fiberoptic bronchoscopy, this invasive procedure may be poorly tolerated by patients with milder disease. The use of non-respiratory specimens such as gastric or stool specimens to diagnose PTB has also been reported but remains controversial [41, 42]. Plasma-based cfDNA assay testing offers a new pathway for PTB diagnosis. Although plasma-based testing such as the interferon gamma release assay may provide indirect evidence of PTB without showing evidence of MTB [43], plasma-based cfDNA testing can provide direct evidence of MTB. Plasma specimens are easily accessible and widely applicable. For PTB patients in whom respiratory specimens are difficult to obtain, plasma cfDNA testing is a convenient and effective alternative diagnostic method. However, the diagnostic efficacy of cfDNA testing using plasma for the diagnosis of PTB was reduced when culture was the reference standard, which may be related to the inconsistent use of reference standards. On the other hand, the use of urine testing for cfDNA might be an alternative diagnostic tool for PTB, but our study showed that the diagnostic efficacy of this method was limited when compared to culture. A recent study showed good efficacy of cfDNA testing using urine for the diagnosis of PTB, but the study used Xpert MTB/RIF as the reference standard [39], which might lead to inconsistent results. However, the studies examined in our meta-analysis focused on adults and lacked data on children. Furthermore, the number of studies that examined cfDNA using plasma and urine for the diagnosis of PTB was limited, as was the number of included patients, so our conclusions should be treated with caution. Future large-scale multicenter studies are needed to confirm the diagnostic efficacy of cfDNA testing.
For EPTB, the categories are even richer. The studies included in this meta-analysis reported three common types of EPTB: tuberculous pleurisy, tuberculous meningitis, and abdominal TB. Our results showed that cfDNA testing had the highest diagnostic value for tuberculous pleurisy, followed by tuberculous meningitis and abdominal TB. All three types are paucibacillary and require invasive procedures to obtain specimens. Their diagnosis is difficult because of the low MTB content in the specimens. Diagnostic efficacy of nucleic acid amplification testing, represented by Xpert MTB/RIF, has remained low in most current studies of paucibacillary tuberculosis. cfDNA may be another effective method to diagnose paucibacillary tuberculosis, although current evidence remains limited. The studies included in our meta-analysis used body fluids (pleural fluid, CSF, and ascites fluid) for cfDNA testing, but not plasma specimens. We further analyzed the diagnostic efficacy of cfDNA testing in EPTB using different types of specimens. Diagnostic efficacy was better with testing plasma samples compared with non-plasma samples. However, the number of included studies was small and the results should be treated cautiously. Studies that used plasma specimens for cfDNA testing did not specifically report efficacy according to type of EPTB, so the efficacy of using plasma for cfDNA testing for different types of EPTB remains unclear. Plasma specimens are easily available and more suitable than body fluid specimens that require invasive procedures to obtain. Therefore, cfDNA plasma testing shows promise as a tool for diagnosing EPTB early. However, further studies are needed.
For different target genes, the diagnostic efficacy of IS6110 might be superior to that of other non-IS6110 target genes (such as IS1081, devR). However, the number of other non-IS6110 target genes included in this study was limited and this result needed to be treated with caution. Only one study included a subset of HIV-positive patients, but this study did not specifically report the effectiveness of cfDNA in diagnosing TB in HIV-positive patients [31]. The diagnostic efficacy of cfDNA in HIV-positive patients is still needs to be further investigated. No studies reported correlation between radiography image of patients and cfDNA test. There are no clear studies on the correlation between imaging results and cfDNA, and further studies can be conducted in this area in the future. Only a few studies had reported the concentration of cfDNA [15, 30], but these studies did not report the effect of different concentrations of cfDNA on the results of the test. Some studies had increased the concentration of cfDNA by increasing the sample volume [30], and the sample volume might be important for cfDNA concentration. However, these are still unclear and need to be confirmed by follow-up studies.
We explored the potential sources of heterogeneity in the studies in our meta-analysis using pre-identified parameters. Meta-regression analysis showed that TB type (PTB or EPTB), specimen type (plasma or non-plasma), PCR method (real-time PCR or digital PCR), and type of study design (prospective or case-control) had no effect on sensitivity and specificity. Target gene (IS6110 or non- IS6110 [IS1081, devR]) and specimen condition (fresh or frozen) affected specificity but not sensitivity. Patient selection method (convenience or consecutive) had an effect on sensitivity but not specificity. Although subgroup analysis showed significant heterogeneity in sensitivity between studies within each subgroup, sensitivity analysis did not identify specific articles as sources of heterogeneity. However, since the heterogeneity in sensitivity was significant, the results must be treated with caution. The included studies also used different CRS references and some did not include radiographic manifestations or treatment response in their CRS criteria. This might be a source of the observed heterogeneity.
There were several limitations in our meta-analysis. First, it was based on individual independent data. Some studies may be missing, despite our best efforts. Second, some studies did not report specific TB and specimen types. Third, the number of studies was limited for some subgroup analyses.
Conclusions
This meta-analysis showed that the performance of cfDNA testing for TB diagnosis (including PTB and EPTB) was good compared with CRS and culture. There was significant heterogeneity in sensitivity and specificity. Diagnostic ability was good for both PTB and EPTB, and the overall diagnostic efficacy for each was similar. For EPTB, subgroup analysis showed that cfDNA had the highest diagnostic value for tuberculous pleurisy, followed by tuberculous meningitis and abdominal TB. Testing efficacy in EPTB was higher with plasma samples compared with non-plasma samples. cfDNA can be used for rapid early diagnosis of TB.
Acknowledgments
We thank the patients and their families who were included in this study, and our colleagues in the department.
References
- 1. Zheng H, Zhong F, Yu G, Shen Y. Comparison of the diagnostic efficacy of the CapitalBio Mycobacterium real-time polymerase chain reaction detection test and Xpert MTB/RIF in smear-negative pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis. 2020. pmid:33242168
- 2. Organization WH. Global Tuberculosis Report 2020. 2020.
- 3. Yu G, Zhao W, Shen Y, Zhu P, Zheng H. Metagenomic next generation sequencing for the diagnosis of tuberculosis meningitis: A systematic review and meta-analysis. PLoS One. 2020;15(12):e0243161. pmid:33259541
- 4. Pang Y, An J, Shu W, Huo F, Chu N, Gao M, et al. Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China, 2008–2017. Emerg Infect Dis. 2019;25(3):457–64. pmid:30789144
- 5. Yang J, Han X, Liu A, Bai X, Xu C, Bao F, et al. Use of Digital Droplet PCR to Detect Mycobacterium tuberculosis DNA in Whole Blood-Derived DNA Samples from Patients with Pulmonary and Extrapulmonary Tuberculosis. Front Cell Infect Microbiol. 2017;7:369. pmid:28848722
- 6. Shen Y, Fang L, Xu X, Ye B, Yu G. CapitalBio Mycobacterium real-time polymerase chain reaction detection test: Rapid diagnosis of Mycobacterium tuberculosis and nontuberculous mycobacterial infection. Int J Infect Dis. 2020;98:1–5. pmid:32553719
- 7. Poeta P, Silva V, Guedes A, Eduardo Pereira J, Cláudia Coelho A, Igrejas G. Tuberculosis in the 21th century: Current status of diagnostic methods. Exp Lung Res. 2018;44(7):352–60. pmid:30663432
- 8. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987;23(6):707–12. pmid:3653190
- 9. Che N, Yang X, Liu Z, Li K, Chen X. Rapid Detection of Cell-Free Mycobacterium tuberculosis DNA in Tuberculous Pleural Effusion. J Clin Microbiol. 2017;55(5):1526–32. pmid:28275073
- 10. Click ES, Murithi W, Ouma GS, McCarthy K, Willby M, Musau S, et al. Detection of Apparent Cell-free M. tuberculosis DNA from Plasma. Sci Rep. 2018;8(1):645. pmid:29330384
- 11. Weerakoon KG, McManus DP. Cell-Free DNA as a Diagnostic Tool for Human Parasitic Infections. Trends Parasitol. 2016;32(5):378–91. pmid:26847654
- 12. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–37. pmid:21562580
- 13. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59(6):1188–91. pmid:10096545
- 14. Gal S, Fidler C, Turner S, Lo YM, Roberts DJ, Wainscoat JS. Detection of Plasmodium falciparum DNA in plasma. Ann N Y Acad Sci. 2001;945:234–8. pmid:11708485
- 15. Ushio R, Yamamoto M, Nakashima K, Watanabe H, Nagai K, Shibata Y, et al. Digital PCR assay detection of circulating Mycobacterium tuberculosis DNA in pulmonary tuberculosis patient plasma. Tuberculosis (Edinb). 2016;99:47–53. pmid:27450004
- 16. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. Jama. 2018;319(4):388–96. pmid:29362800
- 17. Yu G, Shen Y, Ye B, Shi Y. Diagnostic accuracy of Mycobacterium tuberculosis cell free DNA for tuberculosis: A protocol of systematic review and meta-analysis. 2020.
- 18. Leeflang MM. Systematic reviews and meta-analyses of diagnostic test accuracy. Clin Microbiol Infect. 2014;20(2):105–13. pmid:24274632
- 19. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36. pmid:22007046
- 20. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2013;66(2):151–7. pmid:22542023
- 21. Yu G, Zhong F, Ye B, Xu X, Chen D, Shen Y. Diagnostic Accuracy of the Xpert MTB/RIF Assay for Lymph Node Tuberculosis: A Systematic Review and Meta-Analysis. Biomed Res Int. 2019;2019:4878240. pmid:31236407
- 22. Shen Y, Yu G, Zhong F, Kong X. Diagnostic accuracy of the Xpert MTB/RIF assay for bone and joint tuberculosis: A meta-analysis. PLoS One. 2019;14(8):e0221427. pmid:31437232
- 23. J S, M XQ, L LZ, Q W, Y GC, S LY, et al. Diagnostic value of cell free Mycobacterium tuberculosis DNA in effusion pleural for detection of tuberculosis. Chinese journal of pathology. 2018;47(6). pmid:29886594
- 24. Li X, Du W, Wang Y, Liu Z, Li K, Chen H, et al. Rapid Diagnosis of Tuberculosis Meningitis by Detecting Mycobacterium tuberculosis Cell-Free DNA in Cerebrospinal Fluid. Am J Clin Pathol. 2020;153(1):126–30. pmid:31585003
- 25. Shao L, Qiu C, Zheng L, Yang Y, Yang X, Liang Q, et al. Comparison of diagnostic accuracy of the GeneXpert Ultra and cell-free nucleic acid assay for tuberculous meningitis: A multicentre prospective study. Int J Infect Dis. 2020;98:441–6. pmid:32599283
- 26. Sharma P, Anthwal D, Kumari P, Gupta RK, Lavania S, Sharma N, et al. Utility of circulating cell-free Mycobacterium tuberculosis DNA for the improved diagnosis of abdominal tuberculosis. PLoS One. 2020;15(8):e0238119. pmid:32845896
- 27. Yang X, Che N, Duan H, Liu Z, Li K, Li H, et al. Cell-free Mycobacterium tuberculosis DNA test in pleural effusion for tuberculous pleurisy: a diagnostic accuracy study. Clin Microbiol Infect. 2020;26(8):1089.e1–.e6. pmid:31805377
- 28. Han B, Hu L, Yao Y, Cao D. Diagnostic value of plasma Mycobacterium tuberculosis free DNA testing for tuberculosis. Journal of Clinical Pulmonology. 2020;25(6):883–7. Chinese.
- 29. Lyu L, Li Z, Pan L, Jia H, Sun Q, Liu Q, et al. Evaluation of digital PCR assay in detection of M.tuberculosis IS6110 and IS1081 in tuberculosis patients plasma. BMC Infect Dis. 2020;20(1):657. pmid:32894079
- 30. Labugger I, Heyckendorf J, Dees S, Häussinger E, Herzmann C, Kohl TA, et al. Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring. Infection. 2017;45(3):269–76. pmid:27798774
- 31. Patel K, Nagel M, Wesolowski M, Dees S, Rivera-Milla E, Geldmacher C, et al. Evaluation of a Urine-Based Rapid Molecular Diagnostic Test with Potential to Be Used at Point-of-Care for Pulmonary Tuberculosis: Cape Town Cohort. J Mol Diagn. 2018;20(2):215–24. pmid:29269279
- 32. Ahmed N, Mohanty AK, Mukhopadhyay U, Batish VK, Grover S. PCR-based rapid detection of Mycobacterium tuberculosis in blood from immunocompetent patients with pulmonary tuberculosis. J Clin Microbiol. 1998;36(10):3094–5. pmid:9738080
- 33. Fortún J, Martín-Dávila P, Gómez-Mampaso E, González-García A, Barbolla I, Gómez-García I, et al. Extra-pulmonary tuberculosis: differential aspects and role of 16S-rRNA in urine. Int J Tuberc Lung Dis. 2014;18(4):478–85. pmid:24670706
- 34. Duffy FJ, Thompson E, Downing K, Suliman S, Mayanja-Kizza H, Boom WH, et al. A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts. Front Immunol. 2018;9:661. pmid:29706954
- 35. Murugesan K, Hogan CA, Palmer Z, Reeve B, Theron G, Andama A, et al. Investigation of Preanalytical Variables Impacting Pathogen Cell-Free DNA in Blood and Urine. J Clin Microbiol. 2019;57(11). pmid:31511335
- 36. Oreskovic A, Brault ND, Panpradist N, Lai JJ, Lutz BR. Analytical Comparison of Methods for Extraction of Short Cell-Free DNA from Urine. J Mol Diagn. 2019;21(6):1067–78. pmid:31442674
- 37.
Han B. Study on the value of plasma Mycobacterium tuberculosis free DNA test for the diagnosis of tuberculosis. Southern Medical University; 2020. Chinese.
- 38. Cannas A, Goletti D, Girardi E, Chiacchio T, Calvo L, Cuzzi G, et al. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2008;12(2):146–51. pmid:18230246
- 39. Oreskovic A, Panpradist N, Marangu D, Ngwane MW, Magcaba ZP, Ngcobo S, et al. Diagnosing pulmonary tuberculosis using sequence-specific purification of urine cell-free DNA. J Clin Microbiol. 2021. pmid:33789959
- 40. Lu J, Li H, Dong F, Shi J, Yang H, Han S, et al. The Feasibility of Xpert MTB/RIF Testing to Detect Rifampicin Resistance among Childhood Tuberculosis for Prevalence Surveys in Northern China. Biomed Res Int. 2017;2017:5857369. pmid:29359155
- 41. Kabir S, Rahman SMM, Ahmed S, Islam MS, Banu RS, Shewade HD, et al. Xpert Ultra assay on stool to diagnose pulmonary tuberculosis in children. Clin Infect Dis. 2020. pmid:32421765
- 42. Aslam W, Tahseen S, Schomotzer C, Hussain A, Khanzada F, Ul Haq M, et al. Gastric specimens for diagnosing tuberculosis in adults unable to expectorate in Rawalpindi, Pakistan. Public Health Action. 2017;7(2):141–6. pmid:28695088
- 43. Stockbridge EL, Loethen AD, Annan E, Miller TL. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data. PLoS One. 2020;15(12):e0243102. pmid:33270737